Strategic Acquisition Lucas Research was acquired by Centricity Research in December 2023, expanding network reach and capabilities. Sales opportunities include cross-selling studies through the larger network and leveraging Centricity’s platform to accelerate site activation, feasibility, and enrollment in new trials.

High Enrollment Performer Historically a globally-ranked top enroller in diabetes, metabolic, and cardiovascular trials with a 23,000 square foot facility and a 50+ team. Target opportunities include Clinical Trial Management services, patient recruitment partnerships, and site-based feasibility for large, multi-center studies.

Specialized Patient Focus Expertise spans Type 1/Type 2 Diabetes, obesity, fatty liver, thyroid, cardiovascular conditions, and related comorbidities, with interest in vaccine and healthy patient trials. Opportunities exist to partner on trial sites requiring experienced endocrinology and metabolic cohorts and to provide specialized patient recruitment for niche indications.

Local-National Bridge Independent coastal NC site with local access and global enrollment capabilities, offering a bridge between local patient populations and international trials. Potential play involves acting as a premier regional enrollment hub for sponsors seeking diverse demographics and rapid site activation in the southeastern U.S.

Tech and Operations Tech stack includes AWS, Google Cloud, Sentry, and standard CRO tools, with a modern 50+ team and a large facility. Sales angle includes offering integrated site IT and data management support, cloud-based trial logistics, and enhanced monitoring capabilities to sponsors prioritizing data security and operational efficiency.